Menu

References

  1. FEIBA [prescribing information]. Lexington, MA: Takeda Pharmaceutical Company Limited; 2019.
  2. Turecek PL, Váradi K, Gritsch H, Schwarz HP. FEIBA®: mode of action. Haemophilia. 2004;10(suppl 2):3-9.
  3. Antunes SV, Tangada S, Stasyshyn O, et al. Randomized comparison of prophylaxis and on-demand regimens with FEIBA NF in the treatment of haemophilia A and B with inhibitors. Haemophilia. 2014;20(1):65-72.
  4. Data on file.
  5. Négrier C, Lienhart A, Numerof R, et al. SURgical interventions with FEIBA (SURF): international registry of surgery in haemophilia patients with inhibitory antibodies. Haemophilia. 2013;19(3):e143-e150.
  6. Young G, Auerswald G, Jimenez-Yuste V, et al. When should prophylaxis therapy in inhibitor patients be considered? Haemophilia. 2011;17(5):e849-e857.
  7. López-Fernández MF, Altisent Roca C, Álvarez-Román MT, et al. Spanish consensus guidelines on prophylaxis with bypassing agents in patients with haemophilia and inhibitors. Thromb Haemost. 2016;115(5):872-895.
  8. Aledort LM. Factor VIII inhibitor bypassing activity (FEIBA) - addressing safety issues. Haemophilia. 2008;14(1):39-43.
  9. Gomperts ED. FEIBA safety and tolerability profile. Haemophilia. 2006;12(suppl 5):14-19.
  10. Curling J, Goss N, Bertolini J. The history and development of the plasma protein fractionation industry. In: Bertolini J, Goss N, Curling J. Production of Plasma Proteins For Therapeutic Use. Hoboken, New Jersey: John Wiley & Sons, Inc; 2013.
  11. Kingdon HS, Lundblad RL. An adventure in biotechnology: the development of haemophilia A therapeutics—from whole-blood transfusion to recombinant DNA to gene therapy. Biotechnol Appl Biochem. 2002;35(2):141-148.
  12. Grillberger L, Kreil TR, Nasr S, Reiter M. Emerging trends in plasma-free manufacturing of recombinant protein therapeutics expressed in mammalian cells. Biotechnol J. 2009;4(2):186-201.
  13. US Food and Drug Administration. User Fee Billable Biologic Products and Potencies Approved Under Section 351 of the PHS Act. https://www.fda.gov/downloads/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CBER/UCM606472.pdf. Updated October 2018. Accessed February 12, 2019.
  14. Golding B. February 2, 2011 approval letter - FEIBA. U.S. Food and Drug Administration website. http://wayback.archive-it.org/7993/20170112211145/http://www.fda.gov/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/ucm242653.htm. Updated February 8, 2011. Accessed February 12, 2019.
  15. Baxter Receives FDA Approval of FEIBA [Anti-Inhibitor Coagulant Complex] for Prophylactic Treatment of Hemophilia A&B Patients with Inhibitors [news release]. Deerfield, IL: Baxter International, Inc; December 19, 2013. https://investor.baxter.com/investors/events-and-news/news/press-release-details/2013/Baxter-Receives-FDA-Approval-of-FEIBA-Anti-Inhibitor-Coagulant-Complex-for-Prophylactic-Treatment-of-Hemophilia-AB-Patients-with-Inhibitors/default.aspx. Accessed December 10, 2018.
  16. Efficacy and safety study of prophylactic versus on-demand treatment with Feiba NF in subjects with hemophilia A or B and a high titer inhibitor. U.S. National Library of Medicine clinical trials website. https://clinicaltrials.gov/ct2/show/NCT00851721?term=NCT00851721&rank=1#moreinfo. Accessed February 4, 2019.
  17. Váradi K, Negrier C, Berntorp E, et al. Monitoring the bioavailability of FEIBA with a thrombin generation assay. J Thromb Haemost. 2003;1(11):2374-2380.
  18. Treatment Guidelines Working Group, on behalf of the World Federation of Hemophilia (WFH). Guidelines for the Management of Hemophilia. 2nd ed. Montreal, Quebec: World Federation of Hemophilia; 2012:6-73.
  19. National Hemophilia Foundation. MASAC recommendation regarding the use of bypassing agents in patients with hemophilia A or B and inhibitors. MASAC Document #167. https://www.hemophilia.org/Researchers-Healthcare-Providers/Medical-and-Scientific-Advisory-Council-MASAC/MASAC-Recommendations/MASAC-Recommendation-Regarding-the-Use-of-Bypassing-Agents-in-Patients-with-Hemophilia-A-or-B-and-Inhibitors. Published June 3, 2006. Accessed February 12, 2019.
  20. Smejkal P, Brabec P, Matyskova M, et al. FEIBA® in treatment of acute bleeding episodes in patients with haemophilia A and factor VIII inhibitors: a retrospective survey in regional haemophilia centre. Haemophilia. 2009;15(3):743-751.
  21. Rota M, Cortesi PA, Crea R, Gringeri A, Mantovani LG. Thromboembolic event rate in patients exposed to anti-inhibitor coagulant complex: a meta-analysis of 40-year published data. Blood Adv. 2017;1(26):2637-2642.
See LessMore

Cookie Use Notification

We use cookies to ensure that we give you the best experience on our website. By continuing to browse this site, you are agreeing to our use of cookies
as set out in our cookie notice. Please read our cookie notice for more information on the cookies we use and how to delete or block the use of cookies.

      Find out more

Indications for Feiba

FEIBA is an Anti-Inhibitor Coagulant Complex indicated for use in hemophilia A and B patients with inhibitors for:

  • Control and prevention of bleeding episodes

Detailed Important Risk Information

WARNING: EMBOLIC AND THROMBOTIC EVENTS

  • Thromboembolic events have been reported during post-marketing surveillance following infusion of FEIBA,

Indications for Feiba

FEIBA is an Anti-Inhibitor Coagulant Complex indicated for use in
hemophilia A and B patients with inhibitors for:

  • Control and prevention of bleeding episodes
  • Perioperative management
  • Routine prophylaxis to prevent or reduce the frequency of bleeding episodes.

FEIBA is not indicated for the treatment of bleeding episodes resulting from...

Detailed Important Risk Information

WARNING: EMBOLIC AND THROMBOTIC EVENTS

  • Thromboembolic events have been reported during post-marketing surveillance following infusion of FEIBA, particularly following the administration of high doses (above 200 units per kg per day) and/or in patients with thrombotic risk factors.
  • Monitor patients receiving FEIBA for signs and symptoms of thromboembolic events.
;

You are now navigating away from feiba.com

By clicking "OK" below you will be taken to a website that may contain links or references to other websites to which our Privacy Notice may not apply. We encourage you to read the Privacy Policy of every website you visit.

OK Stay on Site

FOR U.S. HEALTHCARE PROFESSIONALS ONLY

The information on this website has been specifically created for U.S. healthcare professionals (HCPs).

Continue to U.S. HCP SiteGo to U.S. Patient Site